Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      NDO D 2
      NDO M 2

      UK-BUO-250027. DOP: May 2025.

      BOTOX®: For treating neurogenic detrusor overactivity (NDO)5

      BOTOX®: significant improvements for NDO patients5,6,7

      X1470 NDO UK BOTOX Sales Aid - New Branding_7 1

      Reduce the impact of NDO symptoms on your patients’ lives.

      Study context: Pooled analysis of two double-blind, placebo controlled, randomised phase 3 clinical studies, in 691 patients with urinary incontinence due to NDO. To assess the efficacy, safety and effects on quality of life of BOTOX® patients with NDO. Mean baseline weekly frequency of UI: 32.4 BOTOX® and 31.5 Placebo.5

      3 reasons to trust BOTOX®

      Licensed in the UK with over 30 years of global experience from across multiple indications1-4

      Over 4 years of continued BOTOX® treatment, durable improvements were seen in NDO symptoms and quality of life8

      BOTOX® provides sustained reduction in daily episodes of UI and urgency for up to 6 cycles5

      BOTOX® is generally well tolerated in NDO5

      Safety and tolerability experience from +30 years of use in a range of conditions2, 3, 5, 9, 10

      I-QoL: Incontinence-quality of life; NDO: neurogenic detrusor overactivity; UI: urinary incontinence.

      VIEW EFFICACY DATA FOR BOTOX®

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Ginsberg D, et al. J Urol. 2012;187:2131-2139.
      7. Cruz F, et al. Eur Urol. 2011;60:742-750.
      8. Rovner E, Kohan A et al. Long-term efficacy and safety of Onabotulinum toxin A in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196(3):801-808
      9. Rothrock J F, Adams JF et al. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Onabotulinum toxin A and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study. European Headache Federation (EHF) 2017; 3rd December presentation
      10. Whitcup SM. Handb Experimental Pharmacol 2019;263:3-10.

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Ginsberg D, et al. J Urol. 2012;187:2131-2139.
      7. Cruz F, et al. Eur Urol. 2011;60:742-750.
      8. Rovner E, Kohan A et al. Long-term efficacy and safety of Onabotulinum toxin A in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196(3):801-808
      9. Rothrock J F, Adams JF et al. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Onabotulinum toxin A and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study. European Headache Federation (EHF) 2017; 3rd December presentation
      10. Whitcup SM. Handb Experimental Pharmacol 2019;263:3-10.

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250044.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.